Clinical trial NCT03705858: Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia
Official title: Postremission Therapy With Actinium-225 (225Ac)-Lintuzumab (Actimab-A®) in Patients With Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Keywords: Acute Myeloid Leukemia
Actinium-225
Lintuzumab
Columbia
Post-remission
Phase I
Lead sponsor: Columbia University
Sponsor class: OTHER
First posted: 2018-10-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see what dose of 225Ac-lintuzumab is safest to give to acute myeloid leukemia (AML) patients who are in remission but still have minimal residual disease (MRD). About 12 subjects will be asked to take part in this phase 1, 3+3 dose-escalation study. In addition to confirming the safety profile of postremission therapy with 225Ac-lintuzumab, preliminary evidence of efficacy will be assessed by estimating progression-free survival (PFS) and overall survival (OS), and serially evaluating for MRD using cytogenetics, fluorescence in situ hybridization (FISH), or flow cytometric assays, as applicable.

Detailed description: Therapy with α particle-emitting constructs of the anti-CD33 monoclonal antibody lintuzumab has demonstrated significant tumor effects in AML. Because therapy is selectively targeted to leukemic blasts, it has the potential advantage of less extramedullary toxicity than conventional systemic agents. Moreover, the unique radiobiological features of α particle emissions may permit more efficient tumor cell kill with greater specificity than treatment with β particle-emitting radioisotopes. Objective responses in AML following treatment with 225Ac-lintuzumab have been seen in cytoreduced disease, either following chemotherapy or using a fractionated dosing scheme.

The presence of MRD detectable by cytogenetic techniques and flow cytometric assays indicates a high risk of relapse for AML patients, despite achieving a clinical complete remission. The high linear energy and short range of α emissions make them ideally suited to eradicate MRD, as suggested by the clinical responses observed in earlier studies. To date, 225Ac-lintuzumab has only been studied in patients with overt leukemia. The aim of this phase 1 study is to identify the maximum tolerated dose (MTD) of 225Ac-lintuzumab that can be given safely to AML patients in the postremission setting in order to eliminate detectable MRD and ultimately prolong PFS and OS.

Eligibility criteria: Inclusion Criteria:

1. Subjects must have histologically confirmed AML in first, second, or third clinical CR/CRp after any standard or investigational therapy.
2. Subjects must have detectable MRD by cytogenetics, FISH, or flow cytometry after the completion of all planned therapy. Detectable MRD by flow cytometry is defined by the presence of a myeloid blast population with an atypical immunophenotype, constituting less than 5% of all events. Examples of planned therapy courses include induction chemotherapy with cytarabine and an anthracycline followed by consolidation chemotherapy or 4-6 cycles of a hypomethylating agent-based regimen.
3. At the time of diagnosis or most recent relapse, greater than 25% of bone marrow blasts must have been CD33 positive.
4. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of 225Ac-lintuzumab in patients \<18 years of age, children are excluded from this study.
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
6. Subjects must have adequate bone marrow and organ function documented within 14 days of study entry as follows:

   1. Absolute neutrophil count (ANC) ≥ 1,000/μL;
   2. Platelet count ≥ 50,000/μL;
   3. Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or estimated glomerular filtration rate of \> 50 mL/min;
   4. Serum total bilirubin ≤ 1.5 × ULN (unless attributable to Gilbert's disease);
   5. Alkaline phosphatase, serum aspartate aminotransferase (AST), and serum alanine aminotransferase (ALT) ≤ 2.5 × ULN.
7. The effects of 225Ac-lintuzumab on the developing human fetus are unknown. Since radiation exposure, however, is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of treatment on study. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of 225Ac-lintuzumab administration.
8. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Subjects with acute promyelocytic leukemia or BCR-ABL-positive leukemia.
2. Subjects who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Prior clofarabine is not allowed due to risk of liver dysfunction.
3. Subjects who have previously received 225Ac-lintuzumab.
4. Subjects with an human leukocyte antigen (HLA)-compatible donor or stem cell source who are immediate candidates for allogeneic hematopoietic cell transplantation (HCT).
5. Subjects who are receiving any other investigational agents concurrently.
6. Subjects with active central nervous system (CNS) involvement by AML.
7. Uncontrolled intercurrent illness including, but not limited to, active serious infections uncontrolled by antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, documented liver cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements.
8. Active malignancy within 3 years of study entry, except previously treated melanoma grade 2 or less, non-melanoma skin cancer, carcinoma in situ or cervical intraepithelial neoplasia, and organ confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) levels and are not on active therapy.
9. Prior organ transplant, including allogeneic HCT.
10. Pregnant or nursing women.
11. Subjects with known human immunodeficiency virus (HIV) infection, active hepatitis B, or active hepatitis C.

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) of postremission therapy
timeFrame: Up to 2 years
Secondary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: Up to 3 years
measure: Overall Survival (OS)
timeFrame: Up to 3 years
Other outcomes:
Locations:
Study officials:
affiliation: Columbia University/Herbert Irving Cancer Center
name: Joseph Jurcic, MD
role: PRINCIPAL_INVESTIGATOR
References: